Request an Appointment
We have appointment times available as soon as the next day. Click below to submit an appointment request.
Xofigo, sometimes called radium 223 dichloride, is a radioactive drug used to treat patients with prostate cancer that has spread only to the bones and who are receiving treatment to lower their testosterone. Typically, this form of cancer has been resistant to medical or surgical treatment.
A decline in testosterone levels is important in these patients because testosterone may cause prostate cancer to grow. Patients who have had drug treatment to lower their testosterone and perhaps surgery and then experience the return of cancer are considered “castration-resistant.”
Xofigo was developed for these patients. It is administered intravenously once every four weeks for a maximum of six doses. Clinical trials have shown that the treatment may extend life for up to 14 months.
View All Our Specialty Cancer Centers
Learn more about Orlando Health Cancer Institute's specialty cancer centers.